Abstract
There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent in vitro activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid interface. Treatment of Syrian Golden hamsters with PF-332 (250 mg/kg, twice daily) completely protected the animals against intranasal infection with the beta (B.1.351) and delta (B.1.617.2) SARS-CoV-2 variants. Moreover, treatment of SARS-CoV-2 (B.1.617.2) infected animals with PF-332 completely prevented transmission to untreated co-housed sentinels.
© 2022. The Author(s).
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
A549 Cells
-
Administration, Oral
-
Animals
-
COVID-19 / prevention & control
-
COVID-19 / transmission
-
COVID-19 / virology
-
COVID-19 Drug Treatment*
-
Chlorocebus aethiops
-
Coronavirus 3C Proteases / antagonists & inhibitors
-
Cricetinae
-
Disease Models, Animal*
-
Humans
-
Lactams / administration & dosage*
-
Lactams / pharmacokinetics
-
Leucine / administration & dosage*
-
Leucine / pharmacokinetics
-
Mesocricetus
-
Nitriles / administration & dosage*
-
Nitriles / pharmacokinetics
-
Proline / administration & dosage*
-
Proline / pharmacokinetics
-
Respiratory Mucosa / drug effects
-
Respiratory Mucosa / virology
-
SARS-CoV-2 / drug effects*
-
SARS-CoV-2 / enzymology
-
SARS-CoV-2 / physiology
-
Vero Cells
-
Viral Protease Inhibitors / administration & dosage*
-
Viral Protease Inhibitors / pharmacokinetics
-
Virus Replication / drug effects
Substances
-
Lactams
-
Nitriles
-
Viral Protease Inhibitors
-
nirmatrelvir
-
Proline
-
3C-like proteinase, SARS-CoV-2
-
Coronavirus 3C Proteases
-
Leucine